PR
CRNX icon

PSP Research’s Crinetics Pharmaceuticals CRNX Stock Holding History

PSP Research’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$412K Hold
11,000
– – 0.22% 32
2026
Q1 		$400K Sell
11,000
-316
-3% -$14.1K 0.28% 49
2025
Q4 		$527K Buy
+11,316
New +$504K 0.46% 53

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PSP Research's CRNX Position: Q2 2026 in Review

PSP Research held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 11,000 shares worth $412K. The position accounts for 0.22% of the portfolio, ranked #32.

PSP Research first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $527K in Q4 2025. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • PSP Research held 11,000 shares of Crinetics Pharmaceuticals worth $412K as of Q2 2026.
  • PSP Research left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up 0.22% of PSP Research's portfolio in Q2 2026, its #32 holding.
  • PSP Research first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Crinetics Pharmaceuticals position peaked at $527K in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.